Biological Vaccine VLA1553
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya Virus Infection
Conditions
Chikungunya Virus Infection
Trial Timeline
Feb 22, 2021 → Jan 26, 2022
NCT ID
NCT04786444About Biological Vaccine VLA1553
Biological Vaccine VLA1553 is a phase 3 stage product being developed by Valneva SE for Chikungunya Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04786444. Target conditions include Chikungunya Virus Infection.
What happened to similar drugs?
0 of 10 similar drugs in Chikungunya Virus Infection were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04786444 | Phase 3 | Completed |
Competing Products
20 competing products in Chikungunya Virus Infection